22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
In a move certain to bring employers some holiday cheer, the NLRB has announced changes to its rules...
Read More >
As discussed in a prior blog post, in Gindel v. Centex Homes, 2018 Fla.App. LEXIS 13019, Florida’s ...
Read More >
On December 19, 2019, the Senate passed, as part of the Further Consolidated Appropriations Act 2020...
Read More >
In a significant ruling of first impression, Solera Holdings, Inc. v. XL Specialty Insurance Co. (“...
Read More >
The Florida Minimum Wage Act, which applies to all employees in Florida covered by the federal minim...
Read More >
Grape Stock Supplier Failed to Rehire a Class of Workers After They Complained of Unequal Treatment,...
Read More >